QLGN - Qualigen Therapeutics Inc
4.18
0.110 2.632%
Share volume: 15,298
Last Updated: Tue 21 Jan 2025 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.75%
PREVIOUS CLOSE
CHG
CHG%
$4.07
0.11
0.03%
Summary score
6%
Profitability
0%
Dept financing
43%
Liquidity
13%
Performance
0%
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Long-term ratios 2020 - 2024
The data are presented for the financials results of the quarters of the last 4 years.
Return on equity
0%
Return on assets
0%
Return on sales
-491.59%
Return on invested capital
0%
Total debt ratio
132.1%
Debt ratio change over timeo
0%
Current Ratio
1.35%
Quick Ratio
1.87%
Cash Position Ratio
0.84%
Short-term ratios 2023 - 2024
The data are presented for the financials results of the quarters of the last year.
Return on equity
0%
Return on assets
0%
Return on sales
0%
Return on invested capital
0%
Total debt ratio
213.92%
Debt ratio change over timeo
0%
Current Ratio
0.43%
Quick Ratio
0.39%
Cash Position Ratio
0.14%
Last quarter ratios 2024
The data are presented for the financials results of the last quarter.
Return on equity
0%
Return on assets
0%
Return on sales
0%
Return on invested capital
0%
Total debt ratio
451.04%
Debt ratio change over time
0%
Current Ratio
0.22%
Quick Ratio
0%
Cash Position Ratio
0.02%
Performance ratios (change over 4 years) 2020 - 2024
The data are presented for the change financials results of the quarter of the last 4 years.
Return on equity
0%
Return on assets
0%
Return on sales
0%
Return on invested capital
0%
Total debt ratio
0%
Debt ratio change over time
0%
Current Ratio
0%
Quick Ratio
0%
Cash Position Ratio
0%
Compare in sector
The following table compares the individual analyzes for the other top 3 stocks within the same industry.
Long-term ratios | QLGN | ABBV | AMGN | VRTX |
---|---|---|---|---|
Return on equity | 0% | 13.03% | 18.15% | 6.63% |
Return on assets | 0% | 2.28% | 3.22% | 5.84% |
Return on sales | -491.59% | 27.95% | 31.46% | 43.41% |
Return on invested capital | 0% | 2.07% | 5.53% | 34.89% |
Profitability | 0% | 45% | 61% | 84% |
Total debt ratio | 132.1% | 91.02% | 90.77% | 24.67% |
Debt ratio change over time | 0% | 435.59% | 17.23% | -0.06% |
Dept financing | 25% | 42% | 18% | 5% |
Current Ratio | 0.43% | 0.82% | 1.41% | 3.64% |
Quick Ratio | 0.39% | 0.71% | 0.99% | 3.42% |
Cash Position Ratio | 0.14% | 0.31% | 0.49% | 2.77% |
Liquididy | 26% | 12% | 27% | 75% |
Short-term ratios | QLGN | ABBV | AMGN | VRTX |
---|---|---|---|---|
Return on equity | 0% | 0% | 0% | 5.91% |
Return on assets | 0% | 1.6% | 2.14% | 4.97% |
Return on sales | 0% | 24.8% | 18.91% | 42.59% |
Return on invested capital | 0% | 0% | 0% | 23.7% |
Profitability | 0% | 23% | 22% | 100% |
Total debt ratio | 213.92% | 94.49% | 93.35% | 24.56% |
Debt ratio change over time | 0% | 0% | 0% | -0.62% |
Dept financing | 50% | 11% | 11% | 3% |
Current Ratio | 0.43% | 0.82% | 1.41% | 3.64% |
Quick Ratio | 0.39% | 0.71% | 0.99% | 3.42% |
Cash Position Ratio | 0.14% | 0.31% | 0.49% | 2.77% |
Liquididy | 7% | 14% | 21% | 75% |